Impact of COVID-19 on clinical trials, page-8

Some one did not get sleep last night. SBM I have just entered and re entered and doing very well thank you. Hyd is difficult for the very reason you just listed. But at least it has FDA app for one of its products and is ready for revenue in Aust next year. Unlike NOX66 which was invented way back in 2012 it is still waiting for phase II and again the shifting goal post is the only thing that is guaranteed for NOX investors. As for KZA I did not dump it I had to sell and that was not my choice. Yep they are doing far better than NOX to which you dumped KZA long ago and missed out all together. Hyd will be making money long before NOX will ever even finish a phaseII trial.